<DOC>
	<DOCNO>NCT02141958</DOCNO>
	<brief_summary>The purpose study assess safety tolerability ascend dos novel oral formulation Fenretinide adult cystic fibrosis ( CF ) patient , once-daily 21 day ( treatment cycle ) . This study include three ( 3 ) dose level minimum 7 day break treatment cycle . For dose level , blood sample collect exploratory pharmacokinetic ( PK ) pharmacodynamic ( PD ) evaluation .</brief_summary>
	<brief_title>Safety Study Fenretinide Adult Patients With Cystic Fibrosis</brief_title>
	<detailed_description>Patients cystic fibrosis innate imbalance essential fatty acid , increase arachidonic acid ( AA ) level , decrease docosahexanoic acid ( DHA ) level , elevate AA/DHA ratio . An increase amount evidence suggest lipid imbalance primary effect CF , play major role infection-inflammation vicious cycle lead respiratory failure . Fenretinide , derivative vitamin A , show correct AA/DHA imbalance lung blood plasma specific animal model CF , result reduce lung inflammation decrease severity pulmonary infection Pseudomonas aeruginosa . This single center , randomize , double-blinded , placebo-controlled Phase 1 clinical study evaluate safety tolerability 3 increase oral dos Fenretinide compare placebo , evaluate pharmacokinetics Fenretinide adult CF patient chronically infect Pseudomonas aeruginosa . A single cohort 16 clinically stable adult patient randomize either Fenretinide placebo , 3:1 randomization scheme ( 12 active , 4 placebo ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Signed Informed Consent Males females 18 year old Diagnosis : Patients must diagnosis cystic fibrosis ( positive sweat chloride test ) confirmation two genetic mutation , one mutation two allele Cystic fibrosis transmembrane conductance regulator ( CFTR ) gene cause Cystic Fibrosis Chronic cystic fibrosis lung disease baseline Forced Exploratory Volume one second equal superior 40 % predict value age , gender height Clinically stable patient enrol study , i.e . stable least one month successful treatment pulmonary exacerbation Chronic pulmonary Pseudomonas aeruginosa colonization and/or infection ( sustained microbiological evidence sputum past 6 month , prior enrollment ) Pancreatic function : Patient must take pancrelipase supplementation diagnose pancreatic insufficiency prescribe physician . Enzyme supplementation modify trial Female patient effective contraceptive method study . Pregnancy : due potential teratogenic effect retinoids , pregnant woman NOT eligible Breastfeeding study patient NOT allow Clinically abnormal renal function : Serum Creatinine &gt; 132 micromoles/L Clinically abnormal liver function : Total bilirubin &gt; 1.5 x Upper Limit Normal range ( ULN ) , Alanine Aminotransferase ( ALT ) and/or Aspartate AminoTransferase ( AST ) &gt; 3 x ULN Alkaline Phosphatase ( ALP ) &gt; 2 x ULN Known history severe allergy sensitivity retinoids Presence cancerous tumor , active remission , treat Presence nyctalopia hemeralopia enrolment , serious retinal , ophthalmological condition ( eg : retinitis pigmentosa , choroidoretinitis xerophthalmia ) , include glaucoma Presence serious dermatological condition entry , include inflammatory xerotic pathology psoriasis ichthyosis Prior therapy Fenretinide . Other retinoids ( eg : vitamin A supplement ) allow , dose regimen remain constant throughout study Participation another drug clinical trial within 30 day prior enrollment Patients , opinion investigator , may able comply safety monitoring requirement study Patients unable comply study protocol followup schedule psychological , familial , sociological geographical reason . Patients known allergy excipients oral capsule formulation propose use study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>